InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,433.74
(
0.23%
)
US TECH 100
19,013.60
(
-0.29%
)
Dow Jones
38,647.10
(
-0.17%
)
Brent Oil
82.92
(
1.15%
)
Bitcoin
67,021.21
(
0.40%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jpinkman

Send PM Follow Ignore
Followers 0
Posts 35
Boards Moderated 0
Alias Born 09/29/2016

jpinkman

Re: jbog post# 77750

Friday, 10/21/2016 9:36:21 AM

Friday, October 21, 2016 9:36:21 AM

Post# of 80490
Suntrust reaffirms their $22 target :


ARIAD weakness creates buying opportunity, says SunTrustSunTrust analyst Yatin Suneja says that ARIAD's stock has been weak following media reports and a letter from Congress regarding the prices of the company's Iclusig drug. But the analyst says that the company has a "highly innovative pipeline addressing significant unmet needs in subsets of cancer patients," Suneja reiterates a $22 price target and Buy rating on the stock.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up